Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Placebo-Controlled, Single Ascending Dose (SAD) Study to Assess the Safety, Tolerability, and Pharmacokinetics of SER-252 in Patients With Parkinson's Disease and Motor Fluctuations

NCT07422675 is registered in ClinicalTrials.gov with Serina Therapeutics as lead sponsor.

NCT NCT07422675
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07422675 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Placebo-Controlled, Single Ascending Dose (SAD) Study to Assess the Safety, Tolerability, and Pharmacokinetics of SER-252 in Patients With Parkinson's Disease and Motor Fluctuations
Lead sponsor
Serina Therapeutics
Phase
Phase 1
Overall status
Recruiting
Start date
February 1, 2026
Completion date
January 31, 2027
Enrollment
40 (estimated)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

advanced parkinson's disease, parkinson disease (disorder)